文章基本信息

标题：Radioiodine treatment for non-toxic goitre
本地全文：下载
作者：Ulla Feldt-Rasmussen
期刊名称：F1000 Biology Reports
电子版ISSN：2051-7599
出版年度：2009
卷号：1
DOI：10.3410/M1-70
语种：English
出版社：Faculty of 1000 Ltd
摘要：There is no ideal treatment for benign multinodular goitre. Besides surgery, which is recommended for large goitres or when malignancy cannot be excluded, the non-surgical treatment options are levothyroxine therapy and radioiodine (¹³¹I) therapy. Conventional ¹³¹I therapy [without recombinant human thyroid-stimulating hormone (rhTSH)] has been used for more than a decade in symptomatic non-toxic multinodular goitre, and although it does lead to significant thyroid volume reduction, relatively high activities of radioiodine are needed because of a frequent finding of a low thyroid radioiodine uptake. rhTSH, even when used in very small doses in combination with ¹³¹I therapy, enhances the thyroid volume reduction at lower ¹³¹I activities by doubling the thyroid radioiodine uptake. However, before rhTSH stimulation can be routinely used by clinicians to optimise the ¹³¹I therapy in multinodular goitre, aspects of this association, such as the cost-benefit and optimum rhTSH dose and safety, will have to be sufficiently clarified.